4 results on '"Jacopo Croce"'
Search Results
2. Atypical hemolytic uremic syndrome: Unique clinical presentation linked to rare CFHR5 mutation
- Author
-
Oliviero Olivieri, Lucia De Franceschi, Enrico Polati, Maurizio Cantini, Matteo Morandi, Martino Donini, Giovanni Gambaro, Francesco Dima, Jacopo Croce, Filippo Mazzi, Sofia Menotti, Sergio De Marchi, Katia Donadello, Giuseppina Pessolano, and Livia Tiro
- Subjects
business.industry ,medicine.medical_treatment ,microangiopathy ,Microangiopathy ,Eculizumab ,medicine.disease ,Complement (complexity) ,plasmapheresis ,Mutation (genetic algorithm) ,Atypical hemolytic uremic syndrome ,Immunology ,medicine ,complement ,eculizumab ,Plasmapheresis ,Presentation (obstetrics) ,business ,CFHR5 ,medicine.drug - Published
- 2021
3. Serum Uric Acid Levels, but Not rs7442295 Polymorphism of SCL2A9 Gene, Predict Mortality in Clinically Stable Coronary Artery Disease
- Author
-
Simonetta Friso, Oliviero Olivieri, Domenico Girelli, Nicola Martinelli, Angela Setti, Jacopo Croce, Chiara Mozzini, Annalisa Castagna, Filippo Stefanoni, and Francesca Pizzolo
- Subjects
medicine.medical_specialty ,Disease ,Coronary Artery Disease ,Hyperuricemia ,030204 cardiovascular system & hematology ,Coronary artery disease ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Risk Factors ,Internal medicine ,medicine ,Humans ,030212 general & internal medicine ,Risk factor ,Polymorphism, Genetic ,Proportional hazards model ,business.industry ,Hazard ratio ,General Medicine ,medicine.disease ,Uric Acid ,chemistry ,Cardiology ,Uric acid ,Gene polymorphism ,Cardiology and Cardiovascular Medicine ,business ,Genome-Wide Association Study - Abstract
Serum uric acid (SUA) has been associated with cardiovascular disease, but up to now whether SUA is an independent cardiovascular risk factor or merely a disease-related epiphenomenon remains still controversial. within the framework of the Verona Heart Study, we prospectively followed 703 subjects with angiographically demonstrated and clinically stable coronary artery disease between May 1996 and March 2007. At baseline, SUA levels were measured in all the patients. Genotype data of SCL2A9 rs7442295 polymorphism, which has been associated with SUA by genome-wide association studies, were available for 686 subjects (97.6%). After a median follow-up of 57 months, 116 patients (16.5%) had died, 83 (11.8%) because of cardiovascular causes. Patients with hyperuricemia, defined by SUA levels above the 75th percentile (≥0.41 mmol/L), had an increased total and cardiovascular mortality rate than those with SUA below this threshold level (23.3% vs 14.1%, P = 0.048 and 19.4% vs 9.2%, P = 0.001, respectively, by Kaplan-Meier with Log-Rank test). These associations were confirmed by Cox regression after adjustment for sex, age, other predictors of mortality, coronary revascularization, and drug therapies at discharge (hazard ratio for total mortality 1.87 [1.05-3.34], P = 0.033; hazard ratio for cardiovascular mortality 2.09 [1.03-4.25], P = 0.041). Although associated with SUA levels, rs7442295 polymorphism did not predict total or cardiovascular mortality. our data support that SUA may be a prognostic cardiovascular biomarker, predicting total and cardiovascular mortality in the setting of secondary prevention of coronary artery disease. On the other hand, SCL2A9 gene polymorphism, notwithstanding a clear influence on SUA levels, was not associated with mortality.
- Published
- 2021
4. Apolipoprotein C-III Strongly Correlates with Activated Factor VII-Anti-Thrombin Complex: An Additional Link between Plasma Lipids and Coagulation
- Author
-
Marcello Baroni, Barry Woodhams, Barbara Lunghi, Filippo Stefanoni, Francesco Bernardi, Jacopo Croce, Domenico Girelli, Federica Tosi, Oliviero Olivieri, Silvia Udali, Nicola Martinelli, and Annalisa Castagna
- Subjects
0301 basic medicine ,Apolipoprotein E ,Male ,Apolipoprotein B ,Coronary Artery Disease ,030204 cardiovascular system & hematology ,Coronary artery disease ,0302 clinical medicine ,medicine.diagnostic_test ,biology ,Anticoagulant ,Thrombin ,Hematology ,Middle Aged ,activated factor VII-anti-thrombin complex ,Lipids ,Observational Studies as Topic ,lipids (amino acids, peptides, and proteins) ,Female ,Glomerular Filtration Rate ,Risk ,medicine.medical_specialty ,Genotype ,medicine.drug_class ,Socio-culturale ,Renal function ,activated factor VII–anti-thrombin complex ,Factor VIIa ,activated factor VII–anti-thrombin complex, APOC3 gene polymorphism, apolipoprotein C-III, coagulation, plasma lipids ,Polymorphism, Single Nucleotide ,Antithrombins ,03 medical and health sciences ,Internal medicine ,plasma lipids ,medicine ,Humans ,coagulation ,Blood Coagulation ,Triglycerides ,Aged ,Apolipoprotein C-III ,business.industry ,APOC3 gene polymorphism ,medicine.disease ,030104 developmental biology ,Endocrinology ,biology.protein ,Lipid profile ,business ,Body mass index ,Genome-Wide Association Study - Abstract
Activated factor VII–anti-thrombin (FVIIa-AT) complex is a potential biomarker of pro-thrombotic diathesis reflecting FVIIa–tissue factor (TF) interaction and has been associated with mortality in patients with coronary artery disease (CAD). Previous data indicated plasma lipids as predictors of FVIIa-AT variability, and plasma lipoproteins as potential stimulators of the coagulation cascade. Our aim was to evaluate the relationships between FVIIa-AT plasma concentration and a broad apolipoprotein profile (including ApoA-I, ApoB, ApoC-III and ApoE). Within the framework of the observational Verona Heart Study, we selected 666 subjects (131 CAD-free and 535 CAD, 75.4% males, mean age: 61.1 ± 10.9 years) not taking anticoagulant drugs and for whom plasma samples were available for both FVIIa-AT assay and a complete lipid profile. Plasma concentration of FVIIa-AT levels significantly and directly correlated with total and high-density lipoprotein cholesterol, triglycerides, ApoA-I, ApoC-III and ApoE levels. ApoC-III showed the strongest correlation (R = 0.235, p = 7.7 × 10−10), confirmed in all the sub-group analyses (males/females and CAD/CAD-free). Only ApoC-III remained associated with FVIIa-AT plasma concentration, even after adjustment for sex, age, CAD diagnosis, body mass index, renal function, smoking status, lipid-lowering therapies and FVIIa levels. The APOC3 gene locus-tagging polymorphism rs964184, previously linked with cardiovascular risk and plasma lipids by genome-wide association studies, was associated with both ApoC-III and FVIIa-AT plasma concentration. Our results indicate a strong association between ApoC-III and FVIIa-AT levels, thereby suggesting that an increased ApoC-III concentration may identify subjects with a pro-thrombotic diathesis characterized by an enhanced TF-FVIIa interaction and activity.
- Published
- 2019
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.